EU/3/07/494

Table of contents

About

On 19 November 2007, orphan designation (EU/3/07/494) was granted by the European Commission to Celgene Europe Limited, UK, for lenalidomide for the treatment of chronic lymphocytic leukaemia.

The sponsorship was transferred to Celgene Europe B.V., The Netherlands, in July 2018.

Key facts

Active substance
lenalidomide
Disease / condition
Treatment of chronic lymphocytic leukaemia
Date of decision
19/11/2007
Outcome
Positive
Orphan decision number
EU/3/07/494

Sponsor's contact details

Celgene Europe B.V.
Winthontlaan 6 N
3526 KV Utrecht
Tel. +31 (0)30 284 4547
E-mail: medinfo.intl@celgene.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating